Short Analytical ReviewUse of Muscarinic Agonists in the Treatment of Sjögren's Syndrome
References (165)
- et al.
The histopathology of Sjögren's syndrome in labial salivary gland biopsies
Oral Surg. Oral Med. Oral Pathol.
(1974) - et al.
Is reduced salivary flow normal in old people?
Lancet
(1990) - et al.
Fas-induced apoptosis is a rare event in Sjögren's syndrome
Lab. Invest.
(2001) - et al.
Conjunctival cytologic features of primary Sjögren's syndrome
Ophthalmology
(1990) Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists
Jpn. J. Pharmacol.
(2000)- et al.
Characterization of muscarinic acetylcholine receptors in human labial salivary glands
Eur. J. Pharmacol.
(1990) Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain
Life Sci.
(1993)- et al.
Structure–function analysis of muscarinic acetylcholine receptors
J. Physiol. (Paris)
(1998) - et al.
Muscarinic acetylcholine receptors: Structural basis of ligand binding and G protein coupling
Life Sci.
(1995) - et al.
Molecular mechanisms involved in muscarinic acetylcholine receptor–mediated G protein activation studied by insertion mutagenesis
J. Biol. Chem.
(1996)
Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands
Eur. J. Pharmacol.
Aquaporin water channel in salivary glands
Jpn. J. Pharmacol.
Persistent increase in the amount of aquaporin-5 in the apical plasma membrane of rat parotid acinar cells induced by a muscarinic agonist SNI-2011
FEBS Lett.
Human recombinant interleukin 1 beta suppresses acetylcholine release from rat myenteric plexus
Gastroenterology
Neuropathogenic actions of cytokines assessed in transgenic mice
Int. J. Dev. Neurosci.
Tumor necrosis factor-alpha and interleukin-1 induce activation of MAP kinase and SAP kinase in human neuroma fibroblasts
Neurochem. Int.
Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome
Am. J. Ophthalmol.
Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome
Ophthalmology
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group
Ophthalmology
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats
Neurosci. Lett.
AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices
Eur. J. Pharmacol.
Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs
Eur. J. Pharmacol.
Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjögren's syndrome
Gen. Pharmacol.
Reduction of cerebrospinal fluid amyloid-beta after systemic administration of M1 muscarinic agonists
Brain Res.
Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: Analysis of 618 patients with suspected Sjögren's syndrome
Arthritis Rheum.
Criteria for the classification of Sjögren's syndrome
Primer on the Rheumatic Diseases
A unified theory of the role of the ocular surface in dry eye
Adv. Exp. Med. Biol.
Diagnosis of keratoconjunctivitis sicca
Int. Ophthalmol. Clin.
Cellulose acetate impressions of the ocular surface: Dry eye states
Arch. Ophthalmol.
Major salivary gland function in primary Sjögren's syndrome and its relationship to clinical features
J. Rheumatol.
Importance of the lipid layer in human tear film stability and evaporation
Optom. Vis. Sci.
Observation of precorneal tear film in patients with Sjögren's syndrome
Acta Ophthalmol. Scand.
Tear film: New concepts and implications for the management of the dry eye
Trans. New Orleans Acad. Ophthalmol.
Sjögren's syndrome: Pathogenesis and new approaches to therapy
Adv. Exp. Med. Biol.
Ocular side effects of selected systemic drugs
Optom. Clin.
Salivary gland dysfunction
Clin. Geriatr. Med.
Diminished submandibular salivary flow in dementia of the Alzheimer type
J. Gerontol.
Salivary gland fluid secretion during aging
J. Am. Geriatr. Soc.
Neurotransmitter control of secretion
J. Dent. Res.
Autonomic control of salivary secretion
Proc. Finn. Dent. Soc.
Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjögren's syndrome
Invest. Ophthalmol. Vis. Sci.
Vasoactive intestinal peptide which coexists with acetylcholine decreases acetylcholine turnover in mouse salivary glands
J. Pharmacol. Exp. Ther.
Distribution of vasoactive intestinal peptide (VIP) and its binding sites in labial salivary glands in Sjögren's syndrome and in normal controls
Clin. Exp. Rheumatol.
Identification and cellular localization of the components of the VIP signaling pathway in the lacrimal gland
Adv. Exp. Med. Biol.
Current issues in the diagnosis and treatment of Sjögren's syndrome
Curr. Opin. Rheumatol.
Expression of granzyme A in salivary gland biopsies from patients with primary Sjögren's syndrome
Arthritis Rheum.
Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome
Arthritis Rheum.
Morphometric analysis of secretory glands in Sjögren's syndrome
Am. Rev. Respir. Dis.
Labial salivary gland biopsy in Sjögren's syndrome
Arthritis Rheum.
Salivary and oral components of Sjögren's syndrome
Rheum. Dis. Clin. North Am.
Cited by (84)
Functionally selective and biased agonists of muscarinic receptors
2021, Pharmacological ResearchCitation Excerpt :The disruption of muscarinic signalling frequently contributes to several pathophysiological conditions in the CNS and in the periphery as well [2]. Thus, muscarinic agonists have a wide therapeutic potential in the treatment of neurological and psychiatric disorders and conditions, e.g. Alzheimer's disease [5], schizophrenia [6] or pain [7,8], and also in some internal diseases like symptoms of xerostomia in Sjögren's syndrome [9] or protection of the heart against the deleriois effects associated with ischaemia or heart failure [10]. To target the above-mentioned diseases, selective modulation of individual muscarinic receptor subtypes is required to avoid undesired side effects.
A review of isolation methods, structure features and bioactivities of polysaccharides from Dendrobium species
2020, Chinese Journal of Natural MedicinesSaliva: An all-rounder of our body
2019, European Journal of Pharmaceutics and BiopharmaceuticsDry Eye Syndrome Preferred Practice Pattern®
2019, OphthalmologyCitation Excerpt :In addition to the treatments for mild and moderate dry eye, the following treatments may be considered for severe dry eye. Oral medications are available to treat severe dry eyes, especially for patients with combined dry eye and dry mouth (Sjögren syndrome).135–137 Cholinergic agonists, pilocarpine, and cevimeline have been approved by the FDA to treat the symptoms of dry mouth in patients with Sjögren syndrome.
Is it Sjögren's syndrome or burning mouth syndrome? Distinct pathoses with similar oral symptoms
2017, Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyCitation Excerpt :However, patients with salivary hypofunction should be encouraged to try these products, as some do experience significant improvement in oral function with their use.109 Patients may find more effective relief with parasympathomimetics, as these drugs actually restore salivary flow, although these are short-acting medications and need be taken immediately before mealtime.110 Patients may be prescribed either pilocarpine hydrochloride or cevimeline, as both are sialagogues that have been approved by the U.S. Food and Drug Administration.111
Mode of interaction of 1,4-dioxane agonists at the M<inf>2</inf> and M <inf>3</inf> muscarinic receptor orthosteric sites
2014, Bioorganic and Medicinal Chemistry Letters
- 1
To whom reprint requests should be addressed at the Allergy and Rheumatology Clinic, 9850 Genesee Ave., #860, La Jolla, CA 92037. Fax: 858-457-2721. E-mail: [email protected].